D&D Pharmatech디앤디파마텍

D&D Pharmatech remains deeply loss-making with heavy debt, and its shares have fallen sharply over the past three months.

The company is a GLP-1 peptide drug developer that earns revenue mainly by licensing early-stage candidates to global partners, including Pfizer for its oral obesity candidates. On trailing twelve-month figures to H1 2026, revenue was about ₩2.8B against an operating loss of about ₩37.6B, and borrowings of about ₩109.6B exceed cash of about ₩12.3B. The share price closed at ₩40,650 on 2026-10-26, well below its 52-week high of ₩116,600.

What stands out

• Trailing revenue of ₩2.8B is tiny compared with the ₩37.6B operating loss, giving an operating margin of about -1,368%.
• Revenue fell from ₩11.4B in 2024 to ₩4.3B in 2025, a decline of 62.4%, and the trailing figure is lower still.
• Liabilities are 138.6% of equity and free cash flow was about -₩24.9B on a trailing basis.
• The share price is down 31.1% over three months and 8.7% over one month, although it is still 3.5% lower over one year.
• Foreign ownership rose from 5.3% to 10.5% over the last 60 days, while foreign investors were net sellers of about ₩13.2B over the last 20 days and retail investors were net buyers of about ₩10.0B.

What to watch

• The next filings and results, including any update on the Pfizer partnership and the amended supply contract filed in July 2026.
• Convertible bond activity, since a conversion-rights exercise and a decision on early redemption of own convertible bonds were both filed in June 2026.
• The major management matter filed on 2026-08-21, whose details are not included in the data provided.